{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:46:34Z","timestamp":1793691994668,"version":"4.5.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T00:00:00Z","timestamp":1570838400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T00:00:00Z","timestamp":1570838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Several major randomized control studies have demonstrated that mepolizumab, an anti-IL-5 monoclonal antibody, is effective for patients with severe eosinophilic asthma who show exacerbation or require systemic corticosteroid maintenance therapy. However, the predictive factors of the response to mepolizumab other than blood eosinophil count are unclear in clinical practice.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To elucidate the predictive factors of the response to mepolizumab for patients with severe eosinophilic asthma.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>From July 2016 to December 2017, 28 patients with severe asthma received mepolizumab in our hospital. To determine the predictive factors, we retrospectively evaluated patient characteristics, comorbidities, biomarkers, pulmonary function, maintenance dose of systemic corticosteroids and number of exacerbations.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The response rate to mepolizumab treatment was 70% (19\/27; one pregnant woman was excluded from analysis). Compared with 11 patients without eosinophilic chronic rhinosinusitis (ECRS), 16 patients with ECRS showed significantly improved systemic corticosteroid-sparing effects [\u2212\u200971.3\u2009\u00b1\u200937.0% vs \u2212\u200910.7\u2009\u00b1\u200920.1%, <jats:italic>P<\/jats:italic>\u2009=\u20090.006], change from baseline FeNO [\u2212\u200919\u2009\u00b1\u200957 (%) vs 30\u2009\u00b1\u200977 (%), <jats:italic>P<\/jats:italic>\u2009=\u20090.023] and symptoms [14 patients (88%) vs five patients (45%), <jats:italic>P<\/jats:italic>\u2009=\u20090.033]. ECRS was identified as a predictive factor of the response to mepolizumab in a multivariate logistic regression analysis [odds ratio\u2009=\u200922.5, 95% CI (1.5\u2013336), <jats:italic>P<\/jats:italic>\u2009=\u20090.024]. Of the eight patients previously administered omalizumab, five responded to mepolizumab. <jats:italic>Staphylococcus aureus<\/jats:italic> enterotoxin B IgE results were negative in 80% of responders (<jats:italic>P<\/jats:italic>\u2009=\u20090.14).<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Both groups showed improved symptom scores and a decreased number of exacerbations. Mepolizumab substantially improved the clinical variables of patients with eosinophilic asthma complicated with ECRS.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-019-0952-1","type":"journal-article","created":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T07:38:14Z","timestamp":1570865894000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2784-2331","authenticated-orcid":false,"given":"Takanori","family":"Numata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsutoshi","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Utsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuo","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Minagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Araya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Kuwano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,12]]},"reference":[{"key":"952_CR1","first-page":"1","volume-title":"Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach","author":"WHO","year":"2007","unstructured":"WHO. Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach; 2007. p. 1\u2013146. Available at \n                    http:\/\/whqlibdoc.who.int\/publications\/2007\/9789241563468_eng.pdf?ua=1\n                    \n                  . Accessed 20 Feb 2018"},{"key":"952_CR2","doi-asserted-by":"publisher","first-page":"443","DOI":"10.2332\/allergolint.10-OA-0282","volume":"60","author":"Y Fukutomi","year":"2011","unstructured":"Fukutomi Y, Taniguchi M, Watanabe J, Nakamura H, Komase Y, Ohta K, et al. Time trend in the prevalence of adult asthma in Japan: findings from population-based surveys in Fujieda City in 1985, 1999, and 2006. Allergol Int. 2011;60:443\u20138.","journal-title":"Allergol Int"},{"key":"952_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.alit.2016.12.005","volume":"66","author":"M Ichinose","year":"2017","unstructured":"Ichinose M, Sugiura H, Nagase H, Yamaguchi M, Inoue H, Sagara H, et al. Japanese guidelines for adult asthma 2017. Allergol Int. 2017;66:163\u201389.","journal-title":"Allergol Int"},{"key":"952_CR4","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jaci.2014.08.042","volume":"135","author":"PPW Hekking","year":"2015","unstructured":"Hekking PPW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135:896\u2013902.","journal-title":"J Allergy Clin Immunol"},{"key":"952_CR5","unstructured":"Global strategy for Asthma Management and Prevention. 2016; Available at \n                    www.ginasthma.org\n                    \n                  . Accessed 21 June 2016."},{"key":"952_CR6","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/j.1365-2222.2011.03929.x","volume":"42","author":"S Wenzel","year":"2012","unstructured":"Wenzel S. Severe asthma:from characteristis to phenotypes to endotypes. Clin Exp Allergy. 2012;42:650\u20138.","journal-title":"Clin Exp Allergy"},{"key":"952_CR7","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","volume":"43","author":"KF Chung","year":"2014","unstructured":"Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343\u201373.","journal-title":"Eur Respir J"},{"key":"952_CR8","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jaip.2017.06.008","volume":"6","author":"PPW Hekking","year":"2017","unstructured":"Hekking PPW, Amelink M, Wener RR, Bouvy ML, Bel EH. Comorbidities in difficult-to-control asthma. J Allergy Clin Immunol Pract. 2017;6:108\u201313.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"952_CR9","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","volume":"3","author":"DB Price","year":"2015","unstructured":"Price DB, Rigazio A, Campbell JD, Bleecker ER, Corrigan CJ, Thomas M, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med. 2015;3:849\u201358.","journal-title":"Lancet Respir Med"},{"key":"952_CR10","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.jaci.2007.03.048","volume":"119","author":"HF Rosenberg","year":"2007","unstructured":"Rosenberg HF, Phipps S, Foster PS. Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol. 2007;119:1303\u201310.","journal-title":"J Allergy Clin Immunol"},{"key":"952_CR11","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","volume":"380","author":"ID Pavord","year":"2012","unstructured":"Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind , placebo-controlled trial. Lancet. 2012;380:651\u20139.","journal-title":"Lancet"},{"key":"952_CR12","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe Eosinophilic asthma. N Engl J Med. 2014;371:1198\u2013207.","journal-title":"N Engl J Med"},{"key":"952_CR13","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","volume":"371","author":"EH Bel","year":"2014","unstructured":"Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of Mepolizumab in Eosinophilic asthma. N Engl J Med. 2014;371:1189\u201397.","journal-title":"N Engl J Med"},{"key":"952_CR14","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.jaci.2017.10.005","volume":"140","author":"SW Yancey","year":"2017","unstructured":"Yancey SW, Keene ON, Albers FC, Ortega H, Bates S, Bleecker ER, et al. Biomarkers for severe eosinophilic asthma. J Allergy Clin Immunol. 2017;140:1509\u201318.","journal-title":"J Allergy Clin Immunol"},{"key":"952_CR15","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1513\/AnnalsATS.201312-454OC","volume":"11","author":"H Ortega","year":"2014","unstructured":"Ortega H, Li H, Suruki R, Albers F, Gordon D, Yancey S. Cluster analysis and characterization of response to mepolizumab: a step closer to personalized medicine for patients with severe asthma. Ann Am Thorac Soc. 2014;11:1011\u20137.","journal-title":"Ann Am Thorac Soc"},{"key":"952_CR16","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.alit.2016.11.006","volume":"66","author":"T Shimoda","year":"2017","unstructured":"Shimoda T, Odajima H, Okamasa A, Kawase M, Komatsubara M, Mayer B, Yancey S, et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergol Int. 2017;66:445\u201351.","journal-title":"Allergol Int"},{"key":"952_CR17","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1164\/rccm.200406-710ST","volume":"171","author":"American Thoracic Society Documents \/ European Respiratory Society","year":"2005","unstructured":"American Thoracic Society Documents \/ European Respiratory Society. Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide , 2005. Am J Respir Crit Care Med. 2005;171:912\u201330.","journal-title":"Am J Respir Crit Care Med"},{"key":"952_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2332\/allergolint.10-RAI-0202","volume":"59","author":"S Takeno","year":"2010","unstructured":"Takeno S, Hirakawa K, Ishino T. Pathological mechanisms and clinical features of Eosinophilic chronic Rhinosinusitis in the Japanese population. Allergol Int. 2010;59:247\u201356.","journal-title":"Allergol Int"},{"key":"952_CR19","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jaci.2009.06.053","volume":"124","author":"M Schatz","year":"2009","unstructured":"Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson ME, Jhingran P, et al. The minimally important difference of the asthma control test. J Allergy Clin Immunol. 2009;124:719\u201323.","journal-title":"J Allergy Clin Immunol"},{"key":"952_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1164\/rccm.201104-0622ED","volume":"184","author":"R Dweik","year":"2011","unstructured":"Dweik R, Boggs P, Erzurum S, Irvin C. An Official ATS Clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for. Am J Respir Crit Care Med. 2011;184:1\u201333.","journal-title":"Am J Respir Crit Care Med"},{"key":"952_CR21","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.jaci.2015.12.1324","volume":"137","author":"P Tomassen","year":"2016","unstructured":"Tomassen P, Vandeplas G, Van Zele T, Cardell LO, Arebro J, Olze H, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137:1449\u201356.","journal-title":"J Allergy Clin Immunol"},{"key":"952_CR22","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.jaip.2016.11.007","volume":"5","author":"JD Blakey","year":"2017","unstructured":"Blakey JD, Price DB, Pizzichini E, Popov TA, Dimitrov BD, Postma DS, et al. Identifying risk of future asthma attacks using UK medical record data: a respiratory effectiveness group initiative. J Allergy Clin Immunol Pract. 2017;5:1015\u201324.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"952_CR23","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/all.13048","volume":"72","author":"RJ Schlosser","year":"2017","unstructured":"Schlosser RJ, Smith TL, Mace J, Soler ZM. Asthma quality of life and control after sinus surgery in patients with chronic rhinosinusitis. Allergy. 2017;72:483\u201391.","journal-title":"Allergy"},{"key":"952_CR24","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/all.12644","volume":"70","author":"T Tokunaga","year":"2015","unstructured":"Tokunaga T, Sakashita M, Haruna T, Asaka D, Takeno S, Ikeda H, et al. Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC study. Allergy. 2015;70:995\u20131003.","journal-title":"Allergy"},{"key":"952_CR25","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1378\/chest.09-0667","volume":"137","author":"G Guida","year":"2010","unstructured":"Guida G, Rolla G, Badiu I, Marsico P, Pizzimenti S, Bommarito L, et al. Determinants of exhaled nitric oxide in chronic rhinosinusitis. Chest. 2010;137:658\u201364.","journal-title":"Chest"},{"key":"952_CR26","doi-asserted-by":"publisher","first-page":"S242","DOI":"10.1067\/mai.2000.110156","volume":"106","author":"JA Denburg","year":"2000","unstructured":"Denburg JA, Sehmi R, Saito H, Pil-Seob J, Inman MD, O\u2019Byrne PM. Systemic aspects of allergic disease: bone marrow responses. J Allergy Clin Immunol. 2000;106:S242\u20136.","journal-title":"J Allergy Clin Immunol"},{"key":"952_CR27","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1067\/mai.2002.122458","volume":"109","author":"A Ten Brinke","year":"2002","unstructured":"Ten Brinke A, Grootendorst DC, Schmidt JT, De Bru\u00efne FT, Van Buchem MA, Sterk PJ, et al. Chronic sinusitis in severe asthma is related to sputum eosinophilia. J Allergy Clin Immunol. 2002;109:621\u20136.","journal-title":"J Allergy Clin Immunol"},{"key":"952_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jaci.2015.05.037","volume":"137","author":"SG Smith","year":"2016","unstructured":"Smith SG, Chen R, Kjarsgaard M, Huang C, Oliveria JP, O'Byrne PM, et al. Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. J Allergy Clin Immunol. 2016;137:75\u201386.e8.","journal-title":"J Allergy Clin Immunol"},{"key":"952_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.alit.2018.11.001","volume":"68","author":"TA Doherty","year":"2019","unstructured":"Doherty TA, Broide DH. Airway innate lymphoid cells in the induction and regulation of allergy. Allergol Int. 2019;68:9\u201316.","journal-title":"Allergol Int"},{"key":"952_CR30","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.jaci.2012.05.012","volume":"130","author":"C Bachert","year":"2012","unstructured":"Bachert C, Van Steen K, Zhang N, Holtappels G, Cattaert T, Maus B, et al. Specific IgE against Staphylococcus aureus enterotoxins: an independent risk factor for asthma. J Allergy Clin Immunol. 2012;130:376\u201381.","journal-title":"J Allergy Clin Immunol"},{"key":"952_CR31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1398-9995.2010.02379.x","volume":"66","author":"ML Kowalski","year":"2011","unstructured":"Kowalski ML, Cie\u015blak M, P\u00e9rez-Novo CA, Makowska JS, Bachert C. Clinical and immunological determinants of severe\/refractory asthma (SRA): association with staphylococcal superantigen-specific IgE antibodies. Allergy. 2011;66:32\u20138.","journal-title":"Allergy"},{"key":"952_CR32","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jaci.2007.08.059","volume":"121","author":"J Patou","year":"2008","unstructured":"Patou J, Gevaert P, Van Zele T, Holtappels G, van Cauwenberge P, Bachert C. Staphylococcus aureus enterotoxin B, protein a, and lipoteichoic acid stimulations in nasal polyps. J Allergy Clin Immunol. 2008;121:110\u20135.","journal-title":"J Allergy Clin Immunol"},{"key":"952_CR33","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1111\/j.1365-2222.2006.02527.x","volume":"36","author":"PW Hellings","year":"2006","unstructured":"Hellings PW, Hens G, Meyts I, Bullens D, Vanoirbeek J, Gevaert P, et al. Aggravation of bronchial eosinophilia in mice by nasal and bronchial exposure to Staphylococcus aureus enterotoxin B. Clin Exp Allergy. 2006;36:1063\u201371.","journal-title":"Clin Exp Allergy"},{"key":"952_CR34","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/cea.12696","volume":"46","author":"KF Chung","year":"2016","unstructured":"Chung KF. Staphylococcal enterotoxin-specific IgE: a biomarker for a distinct phenotype of severe asthma? Clin Exp Allergy. 2016;46:387\u20139.","journal-title":"Clin Exp Allergy"},{"key":"952_CR35","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.3892\/etm.2015.2247","volume":"9","author":"XY Cui","year":"2015","unstructured":"Cui XY, Miao JL, Lu HQ, Qi QH, Chen XI, Xu J, et al. Serum levels of specific IgE to Staphylococcus aureus enterotoxins in patients with chronic rhinosinusitis. Exp Ther Med. 2015;9:1523\u20137.","journal-title":"Exp Ther Med"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-019-0952-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12890-019-0952-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-019-0952-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T23:06:50Z","timestamp":1602371210000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-019-0952-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,12]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["952"],"URL":"https:\/\/doi.org\/10.1186\/s12890-019-0952-1","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,12]]},"assertion":[{"value":"10 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"For this retrospective study, written informed consent from the participants involved was unavailable and unnecessary. The Ethical Committee of Jikei University School of Medicine stated that patient consent was not necessary for this retrospective study. The informed consent was obtained in the form of the bulletin board, or opt-out on the website of our hospital. And this study approved by the Ethical Committee (28\u2013259 (8502)).The director\/administer of Jikei University hospital granted us the permissions to access the medical records.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"176"}}